Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 5/20 | 0.51 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935388 | 1.00 | KCNN4 (0.51) | KCNN4KCNE1KCNQ1CYP2C19HDAC3 | |
| SCHEMBL15535815 | 1.00 | KCNN4 (0.51) | KCNN4KCNE1KCNQ1CYP2C19HDAC3 | |
| SCHEMBL18117413 | 0.85 | KCNN4 (0.47) | KCNN4KCNE1KCNQ1CYP2C19HDAC3 | |
| SCHEMBL20455505 | 0.81 | ALDH1A1 (0.44) | CYP2C19CYP1A2CYP2D6MAPTKMT2A | |
| SCHEMBL15602074 | 0.80 | KCNN4 (0.44) | KCNN4KCNE1KCNQ1CYP2C19HDAC3 | |
| SCHEMBL30501782 | 0.80 | KCNN4 (0.50) | KCNN4KCNE1KCNQ1CYP2C19HDAC3 | |
| SCHEMBL1239901 | 0.80 | KCNN4 (0.50) | KCNN4KCNE1KCNQ1CYP2C19HDAC3 | |
| Hydrochloric Acid SCHEMBL16059704 | 0.79 | KCNN4 (0.42) | KCNN4KCNE1KCNQ1CYP2C19HDAC3 | |
| SCHEMBL11510850 | 0.78 | CYP1A2 (0.44) | CYP2C19CYP1A2CYP2D6MAPTKMT2A | |
| SCHEMBL30883820 | 0.78 | CYP1A2 (0.44) | CYP2C19CYP1A2CYP2D6MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084182-B1 | ANTIDIABETIC COMPOUNDS | CADILA HEALTHCARE LTD (IN) | 2013-08-28 | — | — | EP | claimed |
| EP-0808838-B1 | Sulfur-containing heterocyclic bradykinin antagonists, processes for their production and use thereof | HOECHST AG (DE) | 2003-10-22 | — | — | EP | claimed |
| EP-2855469-B1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| EP-3083644-B1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | disclosed |
| CN-108690052-A | 5- aryl -1- imino group -1- oxos-[1,2,4]Thiadiazine | 豪夫迈·罗氏有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-105683199-B | 5-aryl-1-imino-1-oxo- [1, 2, 4] thiadiazines | 豪夫迈·罗氏有限公司 | 2018-06-26 | — | — | CN | disclosed |
| CN-104334554-B | It is used as 5 amino [Isosorbide-5-Nitrae] thiazide of BACE1 inhibitor | 霍夫曼-拉罗奇有限公司 | 2017-10-31 | — | — | CN | disclosed |
| US-9605006-B2 | 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines | HOFFMANN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN-LA ROCHE INC. (US) | 2016-11-03 | — | — | US | disclosed |
| EP-3083644-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | F. Hoffmann-La Roche AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| CN-105683199-A | 5-aryl-1-imino-1-oxo- [1,2,4] thiadiazines | 豪夫迈·罗氏有限公司 | 2016-06-15 | — | — | CN | disclosed |
| WO-2004076646-A2 | METHODS AND COMPOSITIONS FOR TREATING CERVICAL CANCER | ARBOR VITA CORPORATION (US) | 2004-09-10 | — | — | WO | disclosed |
| EP-1443951-A2 | MOLECULAR INTERACTIONS IN CELLS | Arbor Vita Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1387692-A4 | MOLECULAR INTERACTIONS IN HEMATOPOIETIC CELLS | ARBOR VITA CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004045535-A2 | MOLECULAR INTERACTIONS IN NEURONS | ARBOR VITA CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004022006-A2 | METHODS OF DIAGNOSING CERVICAL CANCER | ARBOR VITA CORPORATION (US) | 2004-03-18 | — | — | WO | disclosed |
| EP-1387692-A2 | MOLECULAR INTERACTIONS IN HEMATOPOIETIC CELLS | Arbor Vita Corporation (US) | 2004-02-11 | — | — | EP | disclosed |
| US-20040018487-A1 | Methods of diagnosing cervical cancer | ARBOR VITA CORPORATION | 2004-01-29 | — | — | US | disclosed |
| WO-2003014303-A2 | MOLECULAR INTERACTIONS IN CELLS | ARBOR VITA CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002042422-A2 | MOLECULAR INTERACTIONS IN HEMATOPOIETIC CELLS | ARBOR VITA CORPORATION (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | BACE1, BACE2, PSEN1 | KCNN4 3568/4885KCNE1 3002/4885KCNQ1 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.